Pharmaceuticals DC $500K+ Reviewed

Barda Drive Ez-Baa (Ezbaa - 22-100-Sol-00003)

HHS

WASHINGTON, DC

vaccines on demand host-directed therapeutics digital MCMs lung therapeutics host diagnostics $500K+

Posted Feb 12, 2024

Due Oct 18, 2027

Description

The BARDA DRIVe EZ-BAA (EZ-BAA-22-100-SOL-00003), issued by HHS, solicits research and development proposals across multiple Areas of Interest (AOIs) focused on medical countermeasures, including ReDIRECT, Lab at Home, Digital MCMs, Host-Directed Therapeutics, Healing Lungs, DRIVe Forward, Vaccines on Demand, ReBooT, Host-Based Diagnostics, and REPAIR. These AOIs target innovative solutions for diagnostics, therapeutics, vaccines, and related technologies to address public health threats. Eligible bidders include biotechnology firms, pharmaceutical companies, academic researchers, and medical device developers with relevant expertise in advanced R&D.

This bid is 98% medical related

A strong match for healthcare vendors

Why we classified this as medical

BARDA (Biomedical Advanced Research and Development Authority) under HHS is issuing a Broad Agency Announcement for medical countermeasures (MCMs), explicitly covering AOIs like Vaccines on Demand, Digital MCMs, Host-Directed Therapeutics, and Healing Lungs, which target pharmaceuticals, vaccines, diagnostics, and therapeutics for public health emergencies. The focus on advanced medical product development by a health security agency confirms direct relevance to medical vendors in these areas.

View Original Source

Save for Later

Send to Pipeline